MedTrace Logo

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

NCT04704947 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-01-12

No results posted yet for this study

Summary

Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis

Conditions

  • Beta Blocker Toxicity

Interventions

DRUG

nonselective beta blocker

nonselective beta blocker

DRUG

cardio-selective beta blocker group

cardio-selective beta blocker group

DRUG

alendronate sodium

alendronate sodium

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Mona Abd El-Rafea Abdo, PH D · Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2030-10-01
Completion
2030-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04704947 on ClinicalTrials.gov